Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 31, 2008

View Archived Issues

Recent Japanese patents describe new agents for endocrine-related disorders

Novel antiinfective agents disclosed in recent patent literature

New immmunosuppressants for preventing transplant rejection reported in recent Rigel patent

Hsp90 inhibitor MPC-3100 active in tumor models

PROTECT-1: 45% clinical remission rate with CCX-282-B in Crohn's disease patients

Parion and Kainos sign clinical development agreement for dry mouth treatment P-552

Allergan and Spectrum collaborate on apaziquone development

Phase I data on Millennium's Aurora A kinase inhibitors available

GlaxoSmithKline to acquire Genelabs Technologies

Radezolid and linezolid equally effective in uncomplicated skin and skin structure infections

DAC initiates phase I/IIa clinical trial of DAC-0060 in non-melanoma skin cancers

Lpath and Merck Serono sign worldwide license agreement for ASONEP monoclonal antibody

Alvine reports results from phase I clinical trial of ALV-003 in celiac disease

Nabi reports final results from phase II immunogenicity study of NicVAX

Snapshots: ACCESS, CHARM, CARE results for adalimumab in Crohn's disease

Preclinical data on D-3263 show anticancer potential of TrpM8 agonism

SuperGen reports on development of JAK2 inhibitor SGI-1252

Karo's phase II study expands the potential for eprotirome in dyslipidemia

Morria presents preliminary results from phase II allergic rhinitis study

Telik reports top-line results from Assist-5 trial in ovarian cancer

Infinity expands phase II study of IPI-504 in advanced non-small cell lung cancer

Takeda submits NDA for Actos combination tablet in Japan

FDA accepts for priority review ImClone and Bristol-Myers' sBLA for Erbitux

FDA grants orphan drug status to Aldagen's ALD-101 stem cell therapy

Patient enrollment complete in RES-ELUTION I trial of Cordis and Conor Medsytems' Nevo stent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...